NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Atrial Fibrillation

First Page		Document Content
Date: 2014-07-30 06:27:48 Amides Amidines Dabigatran CHADS2 score Stroke Management of atrial fibrillation Quality and Outcomes Framework Anticoagulant Apixaban Chemistry Organic chemistry Cardiac dysrhythmia		NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Atrial Fibrillation Add to Reading List Source URL: www.nice.org.uk Download Document from Source Website File Size: 173,08 KB Share Document on Facebook

	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qfnw - View Document
	SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Venous Thromboembolism (VTE) Prevention Following Surgery Pharmaceutical Services Department of Health and Community Serv DocID: 1p0MX - View Document
	SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Novel Oral Anticoagulant (NOAC) for Atrial Fibrillation (AF) Pharmaceutical Services Department o DocID: 1kWDd - View Document
	SPECIAL AUTHORIZATION REQUEST Dabigatran(Pradaxa®), Rivaroxaban(Xarelto®), Apixaban(Eliquis®) Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 SECTION 1 – DocID: 1g5ry - View Document
	DecemberSTROKE PREVENTION IN ATRIAL FIBRILLATION: ROLE OF THE NEWER ORAL ANTICOAGULANTS DocID: 1g4kh - View Document